Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapse prevention study of Lu AA21004 in major depressive disorder
2007-001871-13Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoint: Time to relapse of major depressive episode. Started Oct 2007; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-001871-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001871-13.